A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
Abstract
1. Introduction
2. Results
3. Discussion
4. Material and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- López López, P. Introducción a la Bibliometría; Promolibro: Valencia, Spain, 1996. [Google Scholar]
- Seglen, P.O. Why the impact factor of journals should not be used for evaluating research. BMJ 1997, 314, 5. [Google Scholar] [CrossRef] [PubMed]
- Iftikhar, P.M.; Ali, F.; Faisaluddin, M. A Bibliometric Analysis of the Top 30 Most-cited Articles in Gestational Diabetes Mellitus Literature (1946–2019). Cureus 2019, 11, e4131. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Fernandez, F.J.; Garcia-Fernandez, A.E.; Nava, E. A bibliometric evaluation of the top 100 cited natalizumab articles. J. Neuroimmunol. 2020, 349, 577379. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.H.; Wang, S.Q.; Xue, J.H.; Liu, Y.; Chen, J.Y.; Li, G.F.; He, P.C.; Tan, N. Hundred top-cited articles focusing on acute kidney injury: A bibliometric analysis. BMJ Open 2016, 6, e011630. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, S.S.; Evangelopoulos, D.S.; Abbasian, M. The hundred most-cited publications in orthopaedic knee research. J. Bone Joint Surg. Am. 2014, 96, e190. [Google Scholar] [CrossRef]
- Yeung, A.W.K. The 100 Most Cited Papers Concerning the Insular Cortex of the Brain: A Bibliometric Analysis. Front. Hum Neurosci. 2018, 12, 337. [Google Scholar] [CrossRef]
- Adnan, S.; Ullah, R. Top-cited Articles in Regenerative Endodontics: A Bibliometric Analysis. J. Endod. 2018, 44, 1650–1664. [Google Scholar] [CrossRef]
- Nadri, H.; Rahimi, B.; Timpka, T. The Top 100 Articles in the Medical Informatics: A Bibliometric Analysis. J. Med. Syst. 2017, 41, 150. [Google Scholar] [CrossRef]
- Wipke, B.T.; Hoepner, R.; Strassburger-Krogias, K.; Thomas, A.M.; Gianni, D.; Szak, S.; Brennan, M.S.; Pistor, M.; Gold, R.; Chan, A.; et al. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses. Neurol. Neuroimmunol. Neuroinflammation 2021, 8. [Google Scholar] [CrossRef]
- Chen, H.; Assmann, J.C.; Krenz, A. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J. Clin. Investig. 2014, 124, 2188–2192. [Google Scholar] [CrossRef] [PubMed]
- Linker, R.A.; Lee, D.H.; Ryan, S. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134 Pt 3, 678–692. [Google Scholar] [CrossRef]
- Figueiredo, R.; Quelhas, O.; Vieira Neto, J.; Ferreira, J.J. The role of knowledge intensive business services in economic development: A bibliometric analysis from Bradford, Lotka and Zipf laws. Gest. Prod. 2019, 26, e4356. [Google Scholar] [CrossRef]
- Rizkallah, J.; Sin, D.D. Integrative approach to quality assessment of medical journals using impact factor, eigenfactor, and article influence scores. PLoS ONE 2010, 5, e10204. [Google Scholar] [CrossRef] [PubMed]
- Montes Diaz, G.; Hupperts, R.; Fraussen, J. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun. Rev. 2018, 17, 1240–1250. [Google Scholar] [CrossRef] [PubMed]
Rank # | Article Title | Journal | Year | Times Quoted | No. of Citations Per Year |
---|---|---|---|---|---|
1 | Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis | New England Journal of Medicine | 2012 | 933 | 103.67 |
2 | Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | New England Journal of Medicine | 2012 | 732 | 81.33 |
3 | Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre. Randomised. Double-blind. Placebo-controlled phase IIb study | Lancet | 2008 | 360 | 27.69 |
4 | Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE | Journal of Clinical Investigation | 2014 | 148 | 21.14 |
5 | PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy | New England Journal of Medicine | 2013 | 146 | 18.25 |
6 | PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate | New England Journal of Medicine | 2015 | 133 | 22.17 |
7 | Growth of Campylobacter jejuni supported by respiration of fumarate. Nitrate. Nitrite. Trimethylamine-N-oxide. Or dimethyl sulfoxide requires oxygen | Journal of Bacteriology | 2002 | 128 | 6.74 |
8 | Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview | Therapeutic Advances in Neurological Disorders | 2015 | 124 | 20.67 |
9 | Effects of dimethyl fumarate on neuroprotection and immunomodulation | Journal of Neuroinflammation | 2012 | 124 | 13.78 |
10 | Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity | Science | 2018 | 123 | 41 |
11 | Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor kappa B (NF-kappa B) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling | Journal of Biological Chemistry | 2012 | 120 | 13.33 |
12 | Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 | Proceedings of The National Academy of Sciences of The United States of America | 2016 | 119 | 23.8 |
13 | Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate | Neurology-Neuroimmunology & Neuroinflammation | 2015 | 111 | 18.5 |
14 | The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1 | ASN Neuro | 2011 | 109 | 10.9 |
15 | PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate | New England Journal of Medicine | 2015 | 104 | 17.33 |
16 | Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson’s Disease | Antioxidants & Redox Signaling | 2016 | 100 | 20 |
17 | Electrohydrodimerization Reactions. 2. Rotating Ring-Disk Electrode. Voltammetric and Coulometric Studies of Dimethyl Fumarate. Cinnamonitrile. and Fumaronitrile | Journal of The Electrochemical Society | 1972 | 87 | 1.78 |
18 | Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine—Preparation of S-substituted thiosuccinic acid esters | Bioorganic & Medicinal Chemistry | 2007 | 82 | 5.86 |
19 | Chemistry of Photodimers of Maleic And Fumaric Acid Derivatives. 1. Dimethyl Fumarate Dimer | Journal of The American Chemical Society | 1961 | 79 | 1.32 |
20 | Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis | Neurology-Neuroimmunology & Neuroinflammation | 2016 | 76 | 15.2 |
21 | Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1. NRF2 Activation. And Glutathione Depletion In Vitro | Plos One | 2015 | 73 | 12.17 |
22 | Dimethyl Fumarate for Treatment of Multiple Sclerosis: mechanism of Action, effectiveness and side effects | Current Neurology And Neuroscience Reports | 2013 | 73 | 9.13 |
23 | Role of a singlet exciplex in photocycloaddition of phenanthrene to dimethyl fumarate | Journal of The American Chemical Society | 1974 | 72 | 1.53 |
24 | BG-12 (dimethyl fumarate): a review of mechanism of action efficacy and safety | Current Medical Research and Opinion | 2014 | 71 | 10.14 |
25 | Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK Pathway | International Journal of Molecular Sciences | 2015 | 67 | 11.17 |
26 | Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells | Science Signaling | 2016 | 66 | 13.2 |
27 | Dimethyl fumarate selectively reduces memory t cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients | Journal of Immunology | 2017 | 64 | 16 |
28 | Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE. A randomized extension study | Multiple Sclerosis Journal | 2017 | 64 | 16 |
29 | Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients | Multiple Sclerosis Journal | 2016 | 63 | 12.6 |
30 | Dimethyl fumarate—only an anti-psoriatic medication? | Journal Der Deutschen Dermatologischen Gesellschaft | 2012 | 63 | 7 |
31 | Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway | British Journal of Pharmacology | 2015 | 62 | 10.33 |
32 | Dimethyl fumarate treatment mediates an anti-inflammatory shift in b cell subsets of patients with multiple sclerosis | Journal of Immunology | 2017 | 58 | 14.5 |
33 | Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study | Multiple Sclerosis Journal | 2012 | 51 | 5.67 |
34 | Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation | Biochemical Pharmacology | 2016 | 50 | 10 |
35 | Dimethyl fumarate protects brain from damage produced by intracerebral hemorrhage by mechanism involving Nrf2 | Stroke | 2015 | 50 | 8.33 |
36 | Dimethyl fumarate. An immune modulator and inducer of the antioxidant response. Suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection | Journal of Immunology | 2011 | 50 | 5 |
37 | Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study | Journal of Neurology | 2014 | 49 | 7 |
38 | BG-12 in Multiple Sclerosis | Seminars In Neurology | 2013 | 48 | 6 |
39 | 1.3-Cycloadditions of aliphatic thione s-methylides to dimethyl 2.3-dicyano-fumarate and 2.3-dicyanomaleate—a test case for steric course and mechanism | Tetrahedron Letters | 1989 | 48 | 1.5 |
40 | Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in sh-sy5y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity | Neuroscience | 2015 | 47 | 7.83 |
41 | Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison | Current Medical Research and Opinion | 2014 | 47 | 6.71 |
42 | Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study | Journal of Neurology | 2013 | 47 | 5.88 |
43 | Kinetic-studies on the radical polymerization of isopropyl tert-butyl fumarate initiated with 2.2′-azobis (isobutyronitrile) and dimethyl 2.2′-azobis(isobutyrate)—rates of addition and termination of the primary radicals | Macromolecules | 1992 | 47 | 1.62 |
44 | Singlet and triplet exciplexes in photoreaction of phenanthrene with dimethyl fumarate | Journal of The American Chemical Society | 1975 | 47 | 1.02 |
45 | Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets | Neurology-Neuroimmunology & Neuroinflammation | 2016 | 46 | 9.2 |
46 | Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale. Mechanisms of action. Pharmacokinetics. Efficacy and safety | Expert Review of Neurotherapeutics | 2015 | 46 | 7.67 |
47 | Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study | Journal of Neurology | 2013 | 46 | 5.75 |
48 | Dimethyl fumarate inhibits the Nuclear Factor B pathway in breast cancer cells by covalent modification of p65 protein | Journal of Biological Chemistry | 2016 | 45 | 9 |
49 | Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity | Experimental Neurology | 2015 | 44 | 7.33 |
50 | Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis | Frontiers In Neurology | 2018 | 43 | 14.33 |
51 | Dimethyl fumarate and monomethyl fumarate promote post-ischemic recovery in mice | Translational Stroke Research | 2016 | 43 | 8.6 |
52 | BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis | Journal of Neurology | 2011 | 43 | 4.3 |
53 | [2 + 2] cycloadditions of silyl enol ethers and dimethyl acetylenedicarboxylate. Dimethyl fumarate and methyl crotonate | Journal of Organic Chemistry | 1979 | 43 | 1.02 |
54 | Dimethyl fumarate blocks proinflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation | Scientific Reports | 2016 | 42 | 8.4 |
55 | Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis | CNS Drugs | 2014 | 42 | 6 |
56 | Dimethyl fumarate in multiple sclerosis: latest developments. Evidence and place in therapy | Therapeutic Advances In Chronic Disease | 2016 | 41 | 8.2 |
57 | Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy | Critical Reviews In Immunology | 2013 | 41 | 5.13 |
58 | Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations | Neurology-Clinical Practice | 2016 | 40 | 8 |
59 | Cyclo-additions of N-aryl-C-(trifluoromethyl)nitrilimines with dimethyl fumarate and maleate | Journal of Heterocyclic Chemistry | 1985 | 40 | 1.11 |
60 | Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis | Neurology-Neuroimmunology & Neuroinflammation | 2017 | 39 | 9.75 |
61 | The effect of dimethyl fumarate (Tecfidera (TM)) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk | Multiple Sclerosis And Related Disorders | 2015 | 39 | 6.5 |
62 | The neuroprotective effect of dimethyl fumarate in an MPTP-mouse model of parkinson’s disease: involvement of reactive oxygen species/Nuclear Factor-kappa B/nuclear transcription factor related to NF-e2 | Antioxidants & Redox Signaling | 2017 | 38 | 9.5 |
63 | Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized. Double-blind. Fumaderm (R)—and placebo-controlled trial (BRIDGE) | British Journal of Dermatology | 2017 | 38 | 9.5 |
64 | Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage | Neurobiology of Disease | 2015 | 38 | 6.33 |
65 | Effect of dimethyl fumarate on the radiation sensitivity of mammalian-cells invitro | Radiation Research | 1988 | 38 | 1.15 |
66 | Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis cancer and other diseases | Frontiers In Immunology | 2016 | 37 | 7.4 |
67 | Effects of delayed-release dimethyl fumarate on mri measures in the phase 3 CONFIRM study | Neurology | 2015 | 37 | 6.17 |
68 | Shoe contact dermatitis from dimethyl fumarate: clinical manifestations. Patch test results. Chemical analysis. And source of exposure | Contact Dermatitis | 2009 | 37 | 3.08 |
69 | Electrohydrodimerization reactions. 3. Rotating-ring-disk electrode. Voltammetric and coulometric studies of mixed reductive coupling of dimethyl fumarate in presence of cinnamonitrile and acrylonitrile in dimethylformamide solution | Journal of The Electrochemical Society | 1973 | 37 | 0.77 |
70 | Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate | Annals of Neurology | 2015 | 36 | 6 |
71 | Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study | Multiple Sclerosis Journal | 2014 | 36 | 5.14 |
72 | Dimethyl fumarate for multiple sclerosis | Expert Opinion On Investigational Drugs | 2010 | 36 | 3.27 |
73 | Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes | Redox Biology | 2015 | 35 | 5.83 |
74 | Activation of Nrf2 by dimethyl fumarate improves vascular calcification | Vascular Pharmacology | 2014 | 35 | 5 |
75 | Kinetics of 1.3-dipolar cycloaddition reaction between C.N-diphenylnitrone and dimethyl fumarate in various solvents and aqueous solutions | International Journal of Chemical Kinetics | 2000 | 35 | 1.67 |
76 | Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate | Antioxidants & Redox Signaling | 2017 | 34 | 8.5 |
77 | Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages | Journal of Neuroinflammation | 2016 | 34 | 6.8 |
78 | Dimethyl fumarate. A small molecule drug for psoriasis. Inhibits Nuclear Factor-kappa B and reduces myocardial infarct size in rats | European Journal of Pharmacology | 2008 | 34 | 2.62 |
79 | Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials | Annals of Clinical and Translational Neurology | 2015 | 33 | 5.5 |
80 | Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) | Multiple Sclerosis Journal | 2015 | 33 | 5.5 |
81 | Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers | Clinical Therapeutics | 2013 | 33 | 4.13 |
82 | Synthesis of 3-co-ordinate mono-olefin. Bis-olefin and tris-olefin complexes of platinum with dimethyl or diethyl fumarate, imethyl maleate or maleic-anhydride ligands | Journal of The Chemical Society-Dalton Transactions | 1979 | 33 | 0.79 |
83 | Dimethyl fumarate and the oleanane triterpenoids. Cddo-imidazolide and cddo-methyl ester. Both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis | Carcinogenesis | 2015 | 32 | 5.33 |
84 | Preparation of dimethyl 2-(phenylthio)maleate Dimethyl 2-(phenylthio)fumarate and their sulfoxides | Journal of Organic Chemistry | 1983 | 32 | 0.84 |
85 | Dimethyl fumarate alters B-cell memory and cytokine production in MS patients | Annals of Clinical and Translational Neurology | 2017 | 31 | 7.75 |
86 | PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? | Neurology | 2016 | 31 | 6.2 |
87 | Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience | Neurology and Therapy | 2015 | 31 | 5.17 |
88 | Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis | Therapeutics and Clinical Risk Management | 2014 | 31 | 4.43 |
89 | Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies | European Journal of Neurology | 2017 | 30 | 7.5 |
90 | Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate | Neurology-Neuroimmunology & Neuroinflammation | 2016 | 30 | 6 |
91 | Reactions of exciplex from singlet-excited phenanthrene and dimethyl fumarate-oxetan formation. Intersystem crossing and emission | Journal of The Chemical Society-Chemical Communications | 1972 | 30 | 0.61 |
92 | Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis | Journal of Autoimmunity | 2018 | 29 | 9.67 |
93 | Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting F-kappa B | Blood | 2016 | 29 | 5.8 |
94 | Pharmacodynamics of dimethyl fumarate are tissue specific and involve Nrf2-dependent and -independent mechanisms | Antioxidants & Redox Signaling | 2016 | 29 | 5.8 |
95 | Effects of dimethyl fumarate on lymphocyte subsets | Multiple Sclerosis and Related Disorders | 2015 | 29 | 4.83 |
96 | Solubility of dimethyl fumarate in water plus (methanol. Ethanol. 1-propanol) from (278.15 to 333.15) K | Fluid Phase Equilibria | 2013 | 29 | 3.63 |
97 | Synthesis of (3S.4R)-3.4-isopropylidenedioxy-1-pyrroline-N-oxide. An enantiopure functionalized cyclic nitrone; Cycloaddition reactions with dimethyl maleate and dimethyl fumarate | Synthetic Communications | 1998 | 29 | 1.26 |
98 | Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans | Human Molecular Genetics | 2017 | 28 | 7 |
99 | Dimethyl fumarate associated lymphopenia in clinical practice | Multiple Sclerosis Journal | 2015 | 28 | 4.67 |
100 | Dimethyl fumarate for multiple sclerosis | Cochrane Database of Systematic Reviews | 2015 | 28 | 4.67 |
Author | Affiliation | T100-Record | Times Cited | Average Citations/Record | Average Citations/Year |
---|---|---|---|---|---|
Gold R | Department of Neurology. Perelman School of Medicine, University of Pennsylvania; USA | 12 | 1823 | 130.21 | 140.23 |
Fox RJ | Mellen Center for Multiple Sclerosis; Neurological Institute. Cleveland. USA | 12 | 1211 | 100.92 | 134.56 |
Kappos L | St. Josef Hospital, Department of Neurology Ruhr University, Bochum, Germany. | 12 | 1709 | 142.42 | 131.46 |
Dawson KT | Biogen Idec, Inc. Cambridge, Massachusetts USA | 11 | 2377 | 218.09 | 182.5 |
Phillips JT | Baylor Institute for Immunology Research Dallas, Texas, USA | 10 | 1101 | 110.10 | 122.33 |
Country | T100-Record | Times Cited | Average Citations/Record | Average Citations/Year |
---|---|---|---|---|
USA | 62 | 5258 | 109.54 | 84.81 |
Germany | 30 | 2911 | 207.93 | 97.03 |
England | 16 | 2655 | 63.21 | 165.94 |
Switzerland | 14 | 1862 | 143.23 | 133 |
Czech Republic | 10 | 1440 | 110.77 | 144 |
Institutions | Country | T100-Record | Times Cited | Average Citations/Record | Average Citation Density |
---|---|---|---|---|---|
Biogen | USA | 24 | 3169 | 132.04 | 243.77 |
Ruhr University Bochum | Germany | 15 | 1864 | 124.77 | 143.38 |
University of London | England | 14 | 2494 | 178.14 | 191.85 |
Cleveland Clinic Foundation | USA | 12 | 1211 | 100.92 | 134.65 |
Baylor Scott White Health | USA | 11 | 1165 | 105.91 | 129.44 |
University of Basel | Switzerland | 11 | 1682 | 152.91 | 129.38 |
Journal | T100-Record | Impact Factor | Eigenfactor | Article Influence | Times Cited | Average Citations/Record | Citation Density |
---|---|---|---|---|---|---|---|
Neurology Neuroimmunology Neuroinflammation | 5 | 8.27 | 0.021 | 2.4 | 302 | 60.4 | 50.33 |
New England Journal of Medicine | 5 | 74.70 | 0.682 | 25.7 | 2048 | 409.6 | 227.56 |
Antioxidants Redox Signaling | 4 | 60.39 | - | - | 201 | 50.25 | 40.20 |
Journal of Neurology | 4 | 2.98 | - | - | 185 | 46.25 | 18.50 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
García-Fernández, F.J.; García-Fernández, A.E.; Ikuta, I.; Nava, E.; Solis García del Pozo, J.; Jordan, J.; Galindo, M.F. A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles. Molecules 2021, 26, 1085. https://doi.org/10.3390/molecules26041085
García-Fernández FJ, García-Fernández AE, Ikuta I, Nava E, Solis García del Pozo J, Jordan J, Galindo MF. A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles. Molecules. 2021; 26(4):1085. https://doi.org/10.3390/molecules26041085
Chicago/Turabian StyleGarcía-Fernández, Francisco Javier, Alba Estela García-Fernández, Ichiro Ikuta, Eduardo Nava, Julian Solis García del Pozo, Joaquin Jordan, and Maria F. Galindo. 2021. "A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles" Molecules 26, no. 4: 1085. https://doi.org/10.3390/molecules26041085
APA StyleGarcía-Fernández, F. J., García-Fernández, A. E., Ikuta, I., Nava, E., Solis García del Pozo, J., Jordan, J., & Galindo, M. F. (2021). A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles. Molecules, 26(4), 1085. https://doi.org/10.3390/molecules26041085